Wu et al.14 showed that the complete remission rate of HER-2 positive BC treated with Pyrotinib on the basis of docetaxel and Trastuzumab can reach 41.0%, and the tumor response rate can reach 91.6%, without increasing the incidence of side effects. Here, ERBB2 is linked to neoplasm.